Immuneering (IMRX) AI Stock Analysis

• Market Cap: $208.83M
• Dividend Yield: N/A
• Average Volume (3M): 718.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.40
• Revenue Growth: N/A
• EPS Growth: 0.66%
• Country: US
• Employees: 54
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 36,318,880
• 10 Day Avg. Volume: 1,388,381
• 30 Day Avg. Volume: 718,930
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.47
• Enterprise Value/Revenue: 136.19
• Enterprise Value/Gross Profit: -1.24K
• Enterprise Value/Ebitda: -1.55
• 1Y Price Target: $8.63
• Price Target Upside: 44.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 27 Underperform
• Price Target: ―

Immuneering's stock is primarily challenged by its poor financial performance, with ongoing losses and negative cash flows posing significant risks. Technical indicators suggest bearish momentum, although the oversold RSI may hint at a potential rebound. Valuation metrics are unfavorable, highlighting persistent operational challenges and lack of profitability. The absence of significant earnings call or corporate events data limits further insights.

Positive Factors

Clinical Data

The updated Ph 2a data continues to demonstrate an improved clinical profile, both on efficacy and safety, for the combo in 1L PDAC patients compared to GnP alone.

Management Expertise

The appointment of Dr. Igor Matushansky as the CMO brings extensive oncology drug development expertise to the company.

Strategic Partnerships

A second clinical supply agreement this year with Regeneron for Libtayo further strengthens the company's strategic partnerships.

Negative Factors

Clinical Trial Delays

Other atebimetinib clinical trial combination arms are now expected to initiate in 2026 instead of the previously planned 2025.

Earnings Performance

IMRX reported an EPS of -$0.58 for 4Q24, lower than consensus of -$0.43 with slightly higher R&D ($0.9M var).

Financial Performance

The company reported an earnings per share of -$0.40, which is mostly in line with the consensus of -$0.42.

Immuneering Business Overview & Revenue Model

Company Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

How the Company Makes Money

Immuneering makes money primarily through the development and commercialization of its proprietary drug candidates. The company invests in research and development to advance its pipeline of therapies, with the potential for revenue generation upon successful clinical trials and regulatory approvals. Key revenue streams include milestone payments and royalties from partnerships with larger pharmaceutical companies that may license Immuneering's technology or drug candidates. Additionally, the company may engage in collaborations or licensing agreements to leverage its computational biology platform, providing further financial opportunities.

Immuneering Financial Statement Overview

Summary

Immuneering is facing significant financial challenges, characterized by consistent losses and negative cash flows. The company's ability to generate revenue is concerning, and its operational inefficiencies are reflected in its income statement. While the balance sheet shows a strong equity position, historical leverage issues remain a risk. Cash flow constraints indicate a reliance on external financing to support operations.

Income Statement

Immuneering has consistently reported zero or negative revenue over recent years, indicating significant challenges in generating sales. The gross profit margin is consistently negative or zero, and the net profit margin is deeply negative due to ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet shows a relatively strong equity base with a decreasing trend in total debt. However, the company's equity ratio is fluctuating, and the company has experienced negative stockholders' equity in certain periods, indicating potential financial distress. The debt-to-equity ratio is concerning in some years, pointing to historical leverage issues.

Cash Flow

Operating and free cash flows have been negative, indicating challenges in generating cash from operations. This is coupled with a high dependence on financing activities. The free cash flow to net income ratio cannot be calculated due to persistent net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	726.33K	0.00	0.00	316.95K	2.08M	2.31M
Gross Profit	-80.09K	-713.45K	-764.14K	158.83K	926.89K	1.03M
EBITDA	-63.70M	-63.69M	-58.06M	-51.47M	-33.68M	-17.00M
Net Income	-62.13M	-61.04M	-53.47M	-49.28M	-33.54M	-17.04M
Balance Sheet
Total Assets	40.06M	52.71M	102.58M	122.37M	166.70M	38.42M
Cash, Cash Equivalents and Short-Term Investments	26.36M	36.14M	85.67M	105.52M	149.20M	37.09M
Total Debt	4.00M	4.16M	4.46M	4.84M	5.36M	621.09K
Total Liabilities	11.12M	11.33M	12.01M	12.52M	10.72M	60.90M
Stockholders Equity	28.94M	41.39M	90.58M	109.85M	155.98M	-22.48M
Cash Flow
Free Cash Flow	-51.54M	-55.08M	-49.31M	-44.84M	-30.91M	-14.67M
Operating Cash Flow	-51.51M	-55.00M	-48.97M	-44.10M	-30.85M	-14.62M
Investing Cash Flow	64.14K	26.43M	7.30M	41.83M	-75.62M	-53.41K
Financing Cash Flow	18.07M	5.30M	28.44M	19.00K	144.26M	37.98M

Immuneering Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMRX, the sentiment is Positive. The current price of 5.99 is above the 20-day moving average (MA) of 4.23, above the 50-day MA of 3.95, and above the 200-day MA of 2.32, indicating a bullish trend. The MACD of 0.60 indicates Negative momentum. The RSI at 70.20 is Negative, neither overbought nor oversold. The STOCH value of 84.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMRX.

Immuneering Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.33	-41.57%	2.23%	23.26%	-2.03%
BLUE	51 Neutral		―		―	127.51%	56.94%
DTIL	51 Neutral	$57.76M	2.40	-143.89%	―	-98.56%	-347.81%
MAIA	44 Neutral	$50.81M	―	-459.53%	―	―	62.69%
ACRV	36 Underperform	$42.15M	―	-47.87%	―	―	18.86%
IMRX	27 Underperform	$208.83M	―	-130.47%	―	―	0.66%
ACET	27 Underperform	$59.94M	―	-64.39%	―	―	48.45%